Matinas BioPharma Holdings, Inc.
MTNB evidence brief
What we can confirm
- Market Cap:
- $2.7M
What it means
What to watch
Prepared research question
What matters most for MTNB—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · MTNB
Matinas BioPharma Holdings, Inc. (MTNB) is a clinical-stage biopharmaceutical company developing its lipid nanocrystal (LNC) platform delivery technology, with lead candidate MAT2203 (oral amphotericin B) for invasive fungal infections, currently preparing for a Phase 3 registration trial [sec · filed 2026-06-16].
Key risk: Cash runway risk
Market Cap
$2.7M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Matinas BioPharma Holdings, Inc. (MTNB) is a clinical-stage biopharmaceutical company developing its lipid nanocrystal (LNC) platform delivery technology, with lead candidate MAT2203 (oral amphotericin B) for invasive fungal infections, currently preparing for a Phase 3 registration trial [sec · filed 2026-06-16].
- Clinical-stage biopharmaceutical company focused on lipid nanocrystal (LNC) platform delivery technology [sec_mda · as of 2026-08-13].
- Lead product candidate is MAT2203 (oral amphotericin B), positioned for a single Phase 3 registration trial (ORALTO trial) for invasive aspergillosis [sec · filed 2026-06-16].
- Cash and equivalents of $0.8M as of 2026-06-30 [sec].
- Net income of -$1.3M as of 2026-06-30 [sec].
- Shareholders' equity of $1.8M as of 2026-06-30 [sec].
What works
- MAT2203 has completed a successful EnACT Phase 2 trial in cryptococcal meningitis, de-risking the platform [sec · filed 2026-06-16].
- The LNC platform enables oral delivery of amphotericin B, a potent antifungal, potentially improving safety and tolerability for prolonged use [sec_mda · as of 2026-08-13].
- Company is actively seeking partnerships to monetize MAT2203 and raise non-dilutive capital, which could extend runway [sec_mda · as of 2026-03-31].
What to weigh
- Cash and equivalents of $0.8M as of 2026-06-30 are very limited, and the company expects to incur additional losses for the foreseeable future [sec] [sec_mda · as of 2026-05-08].
- Company has generated no product revenue in recent years and may never achieve profitability [sec_mda · as of 2026-03-31].
- Substantial doubt exists about the company's ability to continue as a going concern without additional financing [sec_mda · as of 2026-03-31].
- Raising adequate capital on acceptable terms is not assured, and failure would negatively impact business strategy [sec_mda · as of 2026-05-08].
From the filings
Quoted directly from source documents.
Company is clinical-stage and uses LNC platform
“We are a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using our lipid nanocrystal (LNC) platform delivery technology (LNC Platform).”
SEC MD&A · August 13, 2026
MAT2203 is lead candidate, Phase 3 trial planned
“MAT2203 is now positioned for a single, Phase 3 registration trial (the "ORALTO trial") in support of a New Drug Application ("NDA") for the treatment of invasive aspergillosis”
SEC filings · June 16, 2026
Cash is insufficient for 12 months
“We do not believe that the cash and cash equivalents on hand are sufficient to fund planned operations beyond the next twelve months from the filing date of this Annual Report.”
SEC MD&A · March 31, 2026
No revenue generated in recent years
“We did not generate any revenue during the years ended December 31, 2025 and 2024.”
SEC MD&A · March 31, 2026
Risks & what to watch (4)›
Key risks
- Cash runway risk — Cash of $0.8M as of 2026-06-30 is very low; company expects losses and may not fund operations beyond 12 months [sec] [sec_mda · as of 2026-03-31].
- Going concern uncertainty — Substantial doubt exists about ability to continue as a going concern without additional financing [sec_mda · as of 2026-03-31].
- No product revenue — Company has generated no revenue from product sales and may never achieve profitability [sec_mda · as of 2026-03-31].
- Financing availability — Adequate financing may not be available on acceptable terms, or at all, threatening business strategy [sec_mda · as of 2026-05-08].
What to watch
- Progress of the ORALTO Phase 3 registration trial for MAT2203 in invasive aspergillosis [sec · filed 2026-06-16].
- Ability to secure partnership or licensing deal for MAT2203 to raise non-dilutive capital [sec_mda · as of 2026-03-31].
- Cash position and any new financing rounds, given cash of $0.8M as of 2026-06-30 [sec].
- Any updates on strategic alternatives, including in-licensing or merger discussions [sec_mda · as of 2026-03-31].
Sources: SEC filings · SEC MD&A · Generated October 2, 2026 · How we verify sources →
Run Matinas BioPharma Holdings, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Matinas BioPharma Holdings, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Financials
Short Interest
as of Apr 21, 2026- % of float
- 0.1%
- Days to cover
- 0.1
- Shares short
- 8,751
- Daily short volume (Jul 24, 2026)
- 40.9%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
MTNB short interestGovernance
Frequently asked questions
What is the AI investment thesis for Matinas BioPharma Holdings, Inc.?
Matinas BioPharma Holdings, Inc. (MTNB) is a clinical-stage biopharmaceutical company developing its lipid nanocrystal (LNC) platform delivery technology, with lead candidate MAT2203 (oral amphotericin B) for invasive fungal infections, currently preparing for a Phase 3 registration trial [sec · filed 2026-06-16].
Who is the CEO of Matinas BioPharma Holdings, Inc.?
Mr. Jerome D. Jabbour J.D. is the chief executive officer of Matinas BioPharma Holdings, Inc. (MTNB).
Where is Matinas BioPharma Holdings, Inc. headquartered?
Matinas BioPharma Holdings, Inc. (MTNB) is headquartered in Bedminster, NJ, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.